Author

Gemma L. Kelly

The University of MelbourneORCID 0000-0002-6533-1201Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 4 Research Focus:cancer & tumor microenvironment· 3 Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Approach:deep learning· 1

Frequent Co-Authors

Andreas StrasseriD· 2 shared Andrew J. KuehiD· 2 shared Laura F. DagleyiD· 2 shared Lauren Whelan· 2 shared Marco J. HeroldiD· 2 shared Margaret A. PottsiD· 2 shared Aisling M. RossiD· 1 shared Allan Shuai HuangiD· 1 shared

Activity by Year

2018-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Andreas StrasserORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A novel, high-density CRISPR activation platform for mapping cancer dependencies and resistance pathways ex vivo and in vivo

Sarah T. Diepstraten, Yexuan Deng, Margaret A. Potts, Amy J. Heidersbach, Christina Koenig, Kristel M. Dorighi, Lin Tai, Andrew J. Kueh, Lauren Whelan, Catherine W.T. Chang, Felix Brown, Gemma L. Kelly, Jean‐Philippe Fortin, Benjamin Haley, John E. La Marca, Marco J. Herold

This paper introduces Partita, a high-density CRISPRa platform for comprehensive gene activation studies, demonstrating its utility in identifying cancer dependencies and resistance pathways in vitro and in vivo.

Science Advances · Sep 18, 2026Peer-reviewedCancer Biology

Pre-existing levels of pro-survival proteins and induction of BCL-XL dictate cell fate after p53 activation

Allan Shuai Huang, Elizabeth Lieschke, Pedro L. Baldoni, Annabella Thomas, Julia M. Marchingo, Lauren Whelan, Grace Khuu, Eddie La Marca, Michael J. G. Milevskiy, Aisling M. Ross, Timothy M. Johanson, Margaret A. Potts, Leonie Gibson, Vineet Vaibhav, Laura F. Dagley, , Andreas Strasser

The paper shows that pre-existing levels of pro-survival proteins and BCL-XL induction determine cell fate after p53 activation, with implications for cancer therapy.

bioRxiv · Jul 2, 2026 · PreprintCancer Biology

MNT loss in MYC-driven B lymphoma cells enhances apoptosis, inhibits proliferation and increases sensitivity to cancer drugs.

Hai Vu Nguyen, Marcel Michla, Feng Yan, N. Davidson, Gemma L. Kelly, Andreas Strasser, Suzanne Cory

This study shows that losing MNT in MYC-driven lymphoma cells increases apoptosis, reduces proliferation, and makes them more sensitive to cancer drugs.

bioRxiv · May 1, 2026 · PreprintCancer Biology

BAX requires VDAC2 to mediate apoptosis and to limit tumor development

Hui San Chin, Mark F. van Delft, Robert L. Ninnis, Mark X. Li, Iris K. L. Tan, Boris Reljic, Kristen Scicluna, Laura F. Dagley, Jarrod J. Sandow, Gemma L. Kelly, Stephane Chappaz, Seong L. Khaw, Catherine Chang, Andrew Webb, Colin Hockings, , Grant Dewson

This study identifies VDAC2 as essential for BAX-mediated apoptosis and tumor suppression, showing BAX and BAK are differentially regulated.

bioRxiv · Feb 16, 2018 · PreprintCell Biology